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Abstract 
Background: Guidelines about post-traumatic stress disorder (PTSD) recommend broad categories of 
drugs, but uncertainty remains about what pharmacological treatment to select among all available 
compounds.  
Methods: Cochrane Central Register of Controlled Trials register, MEDLINE, PsycINFO, National PTSD 
Center Pilots database, PubMed, trial registries and databases of pharmaceutical companies were 
searched until February 2016 for double-blind randomised trials comparing any pharmacological 
intervention or placebo as oral therapy in adults with PTSD. Initially, we performed standard 
pairwise meta-analyses using a random effects model. We then carried out a network meta-analysis. 
The main outcome measures were mean change on a standardised scale and all-cause dropout rate.  
Acute treatment was defined as an 8-week follow up. 
Results: Desipramine, fluoxetine, paroxetine, phenelzine, risperidone, sertraline and venlafaxine 
were more effective than placebo; phenelzine was better than many other active treatments and 
was the only drug, which was significantly better than placebo in terms of dropouts (Odds Ratio 
7.50, 95% CI 1.72-32.80). Mirtazapine yielded a relatively high rank for efficacy, but the respective 
value for acceptability was not among the best treatments. Divalproex had overall the worst ranking. 
Conclusions: The efficacy and acceptability hierarchies generated by our study were robust against 
many sources of bias. The differences between drugs and placebo were small, with the only 
exception of phenelzine. Considering the small amount of available data, these results are probably 
not robust enough to suggest phenelzine as a drug of choice. However, findings from this review 
reinforce the idea that phenelzine should be prioritised in future trials in PTSD. 
Key words: Post-traumatic stress disorder, Systematic review, Network meta-analysis. 
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Background 
Post-traumatic stress disorder (PTSD) is a mental disorder that develops in up to a third of 
individuals who are exposed to extreme stressors, with significant work and social impairment, 
increased risk of suicide, higher medical and social costs and higher psychiatric comorbidity (Norris & 
Sloane, 2007; Steel et al. 2009; Krysinska & Lester, 2010). The estimated lifetime prevalence of PTSD 
among adults in the general population is around 6.8% and current (12-month) prevalence about 
3.6% (WHO, 2011). However, recent surveys of military personnel have yielded higher estimates, 
ranging from 6.2% for U.S. service members who fought in Afghanistan to 12.6% for those who 
fought in Iraq and 15.4% in conflict-affected populations (Dohrenwend et al. 2006; Seal et al. 2007). 
Treatments available for PTSD span a variety of psychological and pharmacological interventions 
(Jonas et al. 2013). Numerous organizations have issued guidance for the treatment of patients with 
PTSD (APA, 2004; NICE, 2005; PA-CPMH, 2013), supporting trauma-focused psychological 
interventions as first-line treatments for PTSD. These guidelines have also recognized some benefit 
of pharmacological interventions; however they have arrived at different conclusions about the 
value of such interventions, and have limited themselves to recommendations about broad 
categories of treatments. From a clinical point of view, though, it is very important to know what 
pharmacological intervention is more efficacious and acceptable than others among the various 
treatment options available for PTSD. Notwithstanding the recent publication of two systematic 
reviews (Watts et al. 2013; Hoskins et al. 2015), clinical uncertainty still remains about what 
pharmacological treatment to select among all available compounds, because traditional pair-wise 
meta-analyses do not allow the simultaneous integration of direct and indirect evidence (Cipriani et 
al. 2013). The aim of this paper is to assess efficacy and acceptability of different pharmacological 
treatments against one another, to provide a clinically useful summary of the comparative evidence 
that can be used to guide decisions about acute treatment of PTSD in adults. 
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Methods 
The study protocol was drafted and made available on our institutional website 
(http://cebmh.warne.ox.ac.uk/cebmh/research_other_reviews.htm) (Appendix 1). Furthermore, 
with the publication of this article, the overall dataset will be in the public domain for anyone who 
would be interested to use it.  
Study eligibility criteria 
We identified all double-blind randomised controlled trials (RCTs) comparing any psychotropic agent 
at a therapeutic dose with another psychotropic drug or placebo as oral therapy in the treatment of 
adults with PTSD, diagnosed according to operationalized criteria. We included both monotherapy 
and add-on studies, and assumed that add-on interventions had an additive effect on the treatments 
of interest. The dose ranges for the medication included in the network meta-analysis were defined 
according to the FDA, whenever possible (https://dailymed.nlm.nih.gov/dailymed/ or 
http://www.accessdata.fda.gov/). If information was not available, we used the British National 
Formulary (https://www.bnf.org/). We included all the following pharmacological interventions: 
amitriptyline, clomipramine, desipramine, imipramine, maprotiline, mianserin, tianeptine, 
trazodone, nefazodone, citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, 
bupropion, desvenlafaxine, venlafaxine, duloxetine, mirtazapine, reboxetine, brofaromine, 
moclobemide, phenelzine (among antidepressants); haloperidol, chlorpromazine, olanzapine, 
risperidone, quetiapine (among antipsychotics); lithium, lamotrigine, valproate, tiagabine, 
topiramate (among mood stabilisers/anti-epileptic drugs); guanfacine, prazosin and selective NK1R 
antagonists (among the new drugs with different mechanisms of action). The synthesis comparator 
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set consists of all the interventions listed above, their combinations and placebo (for all details about 
Methods, see Appendix 1).  
Identification and selection of studies 
We searched Cochrane Depression, Anxiety and Neurosis Group specialised register and the 
Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, PsycINFO, the National 
PTSD Center Pilots database and PubMed (last update: February 15th 2016). We also searched the 
databases of the most important regulatory agencies worldwide and online trial registers for 
published and unpublished RCTs (see Appendix 2 for full details on the search strategy). No language 
restrictions were applied. All relevant authors and principal manufacturers were contacted to 
supplement the incomplete report of the original papers.  
Data collection and study appraisal 
Acute treatment was defined as an 8-week treatment in all analyses. Mean change scores on the 
Clinician-Administered PTSD Scale (CAPS) and dropout rates (treatment discontinuation) were 
chosen as primary outcomes to represent the most sensible and sensitive estimate of acute 
treatment efficacy and acceptability, respectively. As secondary analyses, we also estimated the 
proportion of patients who responded to treatment (according to original study authors’ definition) 
and the proportion of patients who left the study early due to adverse events (tolerability). The risk 
of bias tool was used to assess study quality (Appendix 3) (Higgins & Green, 2011). Additionally, we 
assessed the quality of evidence contributing to each network estimate using the GRADE framework, 
which characterises the quality of a body of evidence on the basis of the study limitations, 
imprecision, inconsistency, indirectness, and publication bias for the primary outcomes (Salanti et 
al., 2014). 
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Data synthesis and statistical analysis 
For continuous outcome, where different measures were used to assess the same outcome, 
standardized mean difference (SMD) (Hedges’s adjusted g) were used (Higgins & Green, 2011; 
Altman & Bland, 1996). Dichotomous outcomes were analyzed by calculating the odds ratio (OR). 
Assessment of clinical and methodological heterogeneity and transitivity  
To evaluate the presence of heterogeneity we generated descriptive statistics for trial and study 
population characteristics across all eligible trials (Furukawa et al. 2006). If the distributions were 
balanced across comparisons, we concluded against evidence of intransitivity (Salanti, 2012; Jansen 
& Naci, 2013). 
Data synthesis 
Initially, we performed standard pairwise meta-analyses using a random effects model (DerSimonian 
& Lair, 1986) in STATA (STATA, 2015). We then carried out a network meta-analysis (NMA) to 
synthesize the available evidence from the entire network of trials by integrating direct and indirect 
estimates and using the methodology of multivariate meta-analysis (different treatment 
comparisons were treated as different outcomes, assuming a common heterogeneity parameter) 
(White et al. 2012). We also estimated the ranking probabilities using the surface under the 
cumulative ranking curve (SUCRA) (Salanti et al. 2011) and mean ranks. To perform NMA we used 
the mvmeta command in Stata (White, 2011) while checking the model assumptions and presenting 
the results we used a suite of previously published Stata commands (Chaimani et al. 2013).  
Statistical heterogeneity and inconsistency 
To measure the percentage of variability that cannot be attributed to random error, we assessed 
statistically the presence of heterogeneity in all pairwise comparisons by calculating the 
heterogeneity standard deviation parameter (τ) and within each comparison using the I-squared 
statistic (Higgins et al. 2003) and its 95% confidence interval (CI). For all outcomes τ was compared 
with its empirical distribution (Turner et al. 2012; Rhodes et al. 2015). We also estimated a total I-
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squared value for heterogeneity in the network (Jackson et al. 2014). We evaluated the presence of 
inconsistency locally (local tests) using the loop-specific approach (Chaimani et al. 2013; Song et al. 
2003; Veroniki et al. 2013). To check the assumption of consistency in the entire network (global 
test) we used the design-by-treatment model (White, 2011; Higgins et al. 2012). To distinguish 
between inconsistency and heterogeneity, we employed the I-squared for inconsistency and 
measured the percentage of variability that cannot be attributed to random error or heterogeneity 
(Turner et al. 2012). In case of important heterogeneity or/and inconsistency, we carried out meta-
regression or subgroup analyses by using the following effect modifiers: (a) variance of the observed 
relative effects; (b) baseline severity; (c) publication year and (d) sponsorship.  
Sensitivity analysis 
To check the robustness of study findings, we carried out a sensitivity analysis excluding studies 
rated as at high or unclear risk of bias (Wood et al. 2008). 
Results 
Description of the evidence base 
The systematic review included overall 51 studies with 6189 patients (see Appendix 4 and 5), 
randomized to 25 different interventions (Figure 1). The mean duration of primary studies was 10.3 
weeks (SD 2.1) and the mean age of trial participants was 42.9 years (SD 5.9). The great majority of 
studies were 2-arm (45 studies), but the search retrieved also six 3-arm studies. Thirty-six studies 
(71.0%) used CAPS (or CAPS-2) as the rating scale for assessing efficacy, with a mean baseline 
severity of 74.1 (SD 16.7). Only 11 trials (22.0%) had an add-on design and overall 36 studies (71.0%) 
were sponsored by pharmaceutical industry. In terms of study quality, the reports often did not 
provide full details about randomisation procedures (28 out of 51, 54.9%) but the reporting about 
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allocation concealment was much worse, as only 19 studies out of 51 (37.2%) were judged at low 
risk of bias (Appendix 3). The networks of eligible comparisons by outcome are shown in Figure 2 
and Appendix 6. The results of the direct pairwise comparisons for all outcomes are reported in 
Appendix 7. There was considerable variability in the placebo response rates among studies, which 
varied between 3% and 60% and resulted in a τ=0.1. However, there was no evidence of a time trend 
in placebo response (p-value 0.93). Heterogeneity was not low only for the dichotomous response 
rate and results did not materially change when we assumed comparison-specific heterogeneity 
parameters.   
Network meta-analysis results 
Table 1 and Figure 3 show the relative treatment effects from NMA for the two primary outcomes 
(change in symptom’s severity and all-cause dropouts). In terms of efficacy, phenelzine, 
desipramine, paroxetine, venlafaxine, fluoxetine, risperidone and sertraline were more effective 
than placebo (Figure 3). Phenelzine appeared to be statistically significantly more effective than 
nearly half of the other active treatments included in the network (9 out of 21), while both 
citalopram and divalproex were statistically significantly less efficacious than phenelzine, 
desipramine and paroxetine (citalopram was also inferior to mirtazapine, olanzapine, venlafaxine 
and fluoxetine) (Table 1). In terms of dropout rate, phenelzine was the only drug which was 
significantly better than placebo (OR 7.50, 95% CI 1.72-32.80) and most of the other active 
treatments (Table 1). No other statistically significant differences were found between the rest of 
the treatments and placebo (Figure 1). Notwithstanding fewer events, response rate data did match 
with our efficacy findings using continuous data (Appendix 8); in terms of dropouts due to adverse 
events, no drug was statistically significantly better tolerated than placebo, but sertraline and 
paroxetine performed worse than placebo (OR 0.59, 95% CI 0.38 to 0.91 and 0.63, 95% CI 0.42 to 
0.94, respectively), and brofaromine better than paroxetine (OR 2.78, 95% CI 1.04 to 7.42), 
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topiramate (OR 4.77, 95% CI 1.04 to 21.75) and sertraline (OR 2.99, 95% CI 1.10 to 8.09) (Appendix 
8). 
We were not able to assess statistically the transitivity assumption by comparing the distributions of 
potential effect modifiers across comparisons as most comparisons were informed by a small 
number of studies. We also evaluated inconsistency in each loop of available evidence (Appendix 9). 
Although we did not find any statistical evidence of inconsistency assuming either network-specific 
or loop-specific heterogeneity, there are a few closed loops per outcome and few studies involved, 
so we cannot exclude the possibility of potentially important inconsistency to be present. The 
design-by-treatment interaction model did not provide evidence that any of the networks presents, 
as a whole, statistically significant inconsistency (Appendix 10); again the small number of closed 
loops and studies limits the power of these tests. The I2 for both heterogeneity and inconsistency in 
NMA were calculated to distinguish between these two sources of variability. For efficacy as 
continuous outcome, I2 was 22.4% for heterogeneity and 22.5% for inconsistency; for acceptability, 
I2 was 0% for heterogeneity and 8% for inconsistency. The percentage of variability attributed to 
heterogeneity was 43.2% for the dichotomous efficacy outcome (we could not derive the respective 
measure for inconsistency as inconsistency could not be assessed for this outcome – see above). For 
dropout rate due to adverse events, I2 was 0% for heterogeneity and 13% for inconsistency. Overall, 
all these measures were in general low but it should be acknowledged that the uncertainty around 
them might be high (see below).  
For a continuous outcome in a “drug versus placebo” comparison in mental health the suggested 
median value for 𝜏 is 0.22 and for a “drug versus drug” comparison it is 0.20. Both values are greater 
than our estimation of heterogeneity for the efficacy as a continuous outcome using the the 
restricted maximum likelihood (REML) estimator (𝜏 = 0.1). For a binary mental health outcome the 
suggested median values for 𝜏 are 0.35 and 0.31 for a “drug versus placebo” and a “drug versus 
drug” comparison, respectively. Our estimation of 𝜏 for the dichotomous efficacy outcome was 0.4, 
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whereas the values of 𝜏 were 0 for all the remaining dichotomous outcomes, dropouts due to any 
cause and dropouts due to adverse events.  
In Figure 4 we used the hierarchical cluster analysis to group treatments according to their ranking 
for the two primary outcomes. Different colours represent different groups of treatments by 
considering jointly their relative ranking for two outcomes (treatments that belong to the same 
group may be considered as being of comparable performance with respect to both outcomes). 
According to all possible cluster rankings, phenelzine performed better than the rest of the 
treatments both in terms of efficacy and dropouts (Appendix 11); this was also supported by 
considering the actual effect sizes presented in Table 1 and Figure 3. Although mirtazapine yielded a 
relatively high rank in the efficacy outcomes, the respective SUCRA value for the dropout outcome 
was 51.5% (Appendix 12). Brofaromine performed well in terms of change in symptoms and adverse 
events, whereas divalproex had the worst ranking considering this particular pair of outcomes. 
Risperidone was the best treatment in terms of response rate whereas it is among the worst for the 
outcome of adverse events. See Appendix 12 for all details about rankings and SUCRA values. We 
could not perform the pre-planned sensitivity analyses because only five studies were rated as low 
risk of bias for allocation concealment (Appendix 3) and because we did not impute any outcome 
data (all information we needed was retrieved by checking for unpublished data and contacting the 
original study authors).  According to GRADE, the quality of evidence for primary outcomes was 
rated as low or very low for most comparisons.  
Impact of effect modifiers  
Because of concerns about power to detect potentially important heterogeneity and inconsistency, 
we applied network meta-regression models to explore the impact on effect modifiers on 
heterogeneity and inconsistency. We included the pre-specified covariates in separate network 
meta-regression models. All results are presented in Appendix 13. For the primary efficacy outcome, 
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the meta-regression model that accounted for baseline severity resulted in a marginally non-
significant coefficient 0.11 (95% CI -0.01, 0.22) implying that the active treatments tended to be 
more effective (compared to placebo) in studies with more severe patients. The estimation of 
heterogeneity (τ) was of 0.1 for both the meta-regression model accounting for baseline severity and 
the model without covariates, showing that accounting for baseline severity did not explain 
heterogeneity. Appendix 14 presents the effect sizes and the treatment hierarchy (using SUCRAs) of 
the standard analysis and those from the meta-regression model at the mean centralized baseline 
severity. Accounting for differences in baseline severity across studies had a minimal impact on the 
effect sizes and the treatment ranking.  
 
The funnel plot analyses suggested a possible association between study precision and dropout due 
to adverse events (Appendix 15).  However, the relative effect estimates derived from the network 
meta-regression model that accounted for small study effects did not converge and drawing 
conclusions based on these findings would be invalid. We performed a random-effects pairwise 
meta-analysis for the comparison active versus placebo which resulted in a summary effect OR of 
1.42 (95%CI: 1.15, 1.75) indicating that placebo is associated with less dropouts due to adverse 
events than active treatments. Accounting for study precision in a meta-regression model resulted in 
a statistically significant coefficient 2.07 (95% CI: 1.10, 3.88). This result suggests that less precise 
studies tended to show placebo to be better tolerated than it would have been in larger studies 
(Appendix 15). 
 
Discussion 
 
Our network meta-analysis provides an evidence based hierarchy for the efficacy and acceptability 
of pharmacological treatments for PTSD, using all available comparative data and thus overcoming 
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the major limitation of previous pairwise meta-analyses (NICE, 2005; Watts et al. 2013; Hoskins et al. 
2015). Interestingly, results from this study challenge the previous dogma that the efficacy of 
psychopharmacological agents within the same drug class is the same. Similarly, clinically important 
differences in efficacy  were found among antipsychotics for schizophrenia (Leucht et al. 2013) and 
also among antidepressants, where differences were reported not only in major depression (Cipriani 
et al. 2009), but also for anxiety disorders, like generalised anxiety disorder (NICE, 2011) and social 
anxiety disorder (NICE, 2013). The efficacy and acceptability hierarchies generated by our study were 
robust against many sources of bias, as various supplementary analyses related to severity at 
baseline, year of publication, small study effect and sponsorship did not change the final ranking to 
an important extent. 
 
We emphasise that the statistically significant differences in efficacy between drugs and placebo 
were small, with the only exception of phenelzine (according to Cohen 1988, an effect size of 0.2 is 
small, 0.5 is medium, and 0.8 is large (Cohen, 1998)). It is probably misleading clinically to dismiss 
the effects of desipramine, fluoxetine, paroxetine, risperidone, sertraline and venlafaxine as being 
small. Their point estimates of SMD were around 0.3, which is the same as antidepressants for 
depression, and indeed for many standard treatments in psychiatry and medicine (Leucht et al., 
2012). Phenelzine had a standardised mean difference of 0.97 when compared with placebo and 
ranged between 0.19 and 1.30 with other active drugs. These differences in efficacy between active 
treatments were possibly substantial enough to be clinically important and pose the question 
whether phenelzine should be used as a first line drug treatment for PTSD. However, the overall 
evidence about this drug is based only on 1 trial with 60 participants. We assessed the contribution 
of this single study to all ‘phenelzine versus other’ network estimates for the primary outcome 
‘change in symptoms’ (Appendix 16 - Figure 1). The only study comparing phenelzine contributes 
more than 35% to the relative effects of all treatments against this specific intervention. Given that 
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the contribution of this study to the relative effects of the rest of the treatment comparisons is very 
low (results not shown but available from the authors), it is therefore unlikely that the retrieved 
evidence can currently be considered robust enough to suggest phenelzine as a drug of choice, 
particularly in view of the need for concomitant dietary restrictions and the risk of drug interactions. 
This is in line with the interpretation of recent clinical practice guidelines (Katzman 2014), however 
our analysis had higher statistical power than previous analyses, because of the comprehensive 
search of published and unpublished data and because we used the network meta-analytical 
method.  
 
Phenelzine is a potent inhibitor of monoamine oxidase (MAOI), licensed in the US and UK for 
depressed patients clinically characterized as “atypical,” “non-endogenous,” or “neurotic”, who 
often have mixed anxiety and depression and phobic or hypochondriacal features 
(http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/011909s038lbl.pdf). Even though 
approved for depression only, phenelzine is also effective in the treatment of anxiety disorders such 
as panic disorder and social phobia (Sheean et al. 1980; Johnson et al. 1994). Of course phenelzine, 
may owe its apparently striking efficacy in PTSD to the expected increases of brain levels of biogenic 
amines (serotonin, noradrenaline and dopamine) produced by MAO inhibition. However, the 
reversible MAOI-A inhibitor, brofaromine, was of only modest efficacy in the current analysis. It may 
therefore be relevant that unlike other MAOIs, phenelzine also possesses the ability (at least in 
animal studies) to increase brain levels of the inhibitory neurotransmitter, γ-aminobutyric acid 
(GABA), through blocking the GABA metabolising enzyme, GABA transaminase. Studies with 
magnetic resonance spectroscopy (MRS) indicate that cortical GABA levels may be lower in patients 
with PTSD (Rosso et al. 2014). Hence the efficacy of phenelzine in PTSD might result from a 
combination of monoamine and GABA potentiation. However, it is also possible that GABA 
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transaminase inhibition by itself, for example with the anticonvulsant drug vigabatrin, could be a 
viable therapeutic strategy in PTSD  
 
Interestingly, treatment with phenelzine reduces dream recall frequency (Landolt et al. 2001) and 
induces almost total REM sleep suppression in anxious-depressed patients (Wyatt et al. 1971). 
Although objective sleep findings in PTSD are mixed, there is some evidence that REM sleep 
fragmentation and REM sleep autonomic imbalance are associated with an increased risk for the 
development and persistence of PTSD (Mellman et al. 2007). Sleep disturbances are an indicator of 
heightened risk for poor psychiatric outcomes following trauma exposure (Geermain, 2013). To date 
prazosin (an alpha-1 antagonist) is the recommended pharmacological treatment options for PTSD-
related nightmares, as it is associated with improvements in nightmares and insomnia (Aurora et al. 
2010). In our analysis prazosin was not among the most efficacious treatments for relieving acute 
symptoms of PTSD, so the fact that phenelzine may reduce  the REM sleep disturbances associated 
with PTSD could also give it additional benefit over drugs like SSRIs and SNRIs which also lower REM 
sleep, but to a lesser extent than phenelzine (Sharpley & Cowen, 1995). 
 
Our study has several limitations. The validity of the above findings might be limited due to the lack 
of sufficient data to properly evaluate the required assumptions. Results from network meta-
analysis may be unreliable when there is a high risk for intransitivity in the network (Cipriani et al. 
2013; Salanti, 2012). Statistical assessment of the transitivity assumption (i.e. one can learn 
indirectly for a pairwise comparison via one or more anchor treatments) considers whether the 
distribution of the potential effect modifiers is balanced across the available direct comparisons. In 
our network we were unable to judge the plausibility of transitivity since most comparisons included 
very few studies. Thus, we could only rely on our clinical understanding of the studied condition and 
outcomes to assume that transitivity was likely to hold in the identified data. Important intransitivity 
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might be reflected in the data in the form of statistical inconsistency. Our network included only few 
closed loops of evidence, for which inconsistency could be assessed (3 loops for efficacy as 
continuous outcome, 2 for all-cause dropout, none for response rate and 2 for dropouts due to 
adverse events). Using the loop-specific approach and the design-by-treatment interaction model 
we did not find any statistically significant inconsistency (Higgins et al. 2012; Song et al. 2003). 
However, the tests for inconsistency very often have low power and may fail to detect inconsistency 
as statistically significant even when it is present (Veroniki et al. 2013). Inconsistency is closely 
related with heterogeneity and the two notions should be considered jointly. The small number of 
studies in the majority of the available direct comparisons renders the assessment of comparison-
specific heterogeneities impractical (when it is estimable). The common heterogeneity across all 
comparisons from the network meta-analysis was estimated close to zero and the I2 measure for 
heterogeneity suggested that heterogeneity was low in the network. This finding slightly mitigates 
our concerns for the reliability of our results. However, all statements comparing the drugs in the 
network must be tempered by the potential limitations of the methodology, the complexity of 
patients with PTSD and the uncertainties that may result from choice of dose or treatment setting. 
 
We explored the association of several characteristics and their impact on the relative effects using 
network meta-regression models. The model accounting for baseline severity for the efficacy 
primary outcome resulted in a marginally non-statistically significant regression coefficient 
suggesting that the active treatments have a tendency to appear more effective (when compared to 
placebo) in studies with more severe populations. The meta-regression model that accounted for 
small-study effects for the outcome of adverse events suggested that small studies showed the 
placebo safer than did larger studies. This finding might be due to publication bias or selective 
reporting bias, or might be the manifestation of other characteristics such as study quality (Chaimani 
& Salanti, 2012; Chaimani et al. 2013). Despite this finding, we were unable to use the results from 
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this model for drawing conclusions with respect to the relative safety of the treatments due to the 
lack of convergence for the estimated relative effect.   
Most trials included in our analysis did not report adequate information about randomisation and 
allocation concealment, and this might undermine the validity of overall findings. However, all the 
studies were double-blind and the scant information in terms of quality assessment could be more 
an issue of reporting in the text than real defects in study design, as it has been commonly found in 
other systematic reviews (Huwiler- Müntener et al. 2002). Finally, findings from this analysis apply 
only to acute-phase treatment of PTSD. Clinically, the assessment of efficacy after 4 weeks of 
treatment or after 16 weeks or more might lead to wide differences in treatment outcome, and this 
may limit the ability to provide valid estimates of treatment effect if different durations of follow-up 
are combined. To overcome this problem, we employed a common definition of acute response that 
included a pre-defined follow-up duration (8 weeks). Moreover, because network meta-analysis 
requires reasonably homogeneous studies, in this project we had to restrict ourselves to short-term 
trials and decided to address the issue of long term relapse prevention treatment in an ad hoc 
network meta-analysis, as we previously did for bipolar disorder (Cipriani et al. 2011; Miura et al. 
2014). 
 
All-cause discontinuation has been used in other NMAs as a measure for the acceptability of 
treatments, because it encompasses at the same time efficacy and tolerability. Response rate and 
dropout rate were chosen as primary outcomes to have the best estimate of acute 
treatment effectiveness (Cipriani et al. 2009; Leucht et al. 2013). In our analysis, the results 
paralleled the efficacy findings in that phenelzine, the most effective drug, also had the lowest 
discontinuation rates. We used the neutral term all-cause discontinuation, because clinicians might 
intuitively associate the word acceptability more with tolerability than with efficacy. However, it is 
worth noting that phenelzine, even though not statistically significant, showed a trend of better 
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tolerability in terms of dropout rate due to adverse events when compared with placebo. Even if in 
clinical practice MAOIs are used much less frequently than other antidepressant agents because of 
the dangers of dietary and drug interactions (http://www.bnf.org/bnf/index.htm), findings from this 
review reinforce the idea that phenelzine should be prioritised in future trials in PTSD, particularly in 
the significant proportion of patients who remain symptomatic despite first-line psychological and 
pharmacological treatments. It would also be of interest to use magnetic resonance spectroscopy to 
assess the effect of phenelzine treatment on GABA levels in the human brain and to relate 
symptomatic improvement in PTSD symptomatology to changes in GABA concentration.
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Figure legends 
 
 
Figure 1: PRISMA flow diagram. Included and excluded studies.  
 
Figure 2: Network plot for the primary efficacy outcome. Nodes and edges are weighted according 
to the number of studies involved in each treatment comparison 
 
 
Figure 3: Network meta-analysis results for the comparisons of active treatments versus placebo 
for the primary outcomes (a) change in symptoms and (b) all-cause dropouts (reference 
treatment: placebo). Legend: SMD: Standardised Mean Difference; OR: Odds Ratio; CI: Credibility 
Interval. Effect sizes are listed on the basis of SUCRA rankings. Statistically significant results are 
highlighted in red.   
 
 
Figure 4: Clustered ranking based on SUCRA values for the outcomes ‘Change in symptoms’ 
(unadjusted model) and ‘Any cause dropouts’. Hierarchical cluster analysis is performed to group 
the competing treatments. Different colors represent different groups according to treatments’ 
similarity regarding the two outcomes. 
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0.43 
(-0.03, 0.90) 
0.63 
(0.02, 1.24) 
_ 
4.09 
(1.04, 16.15) 
0.64 
(0.08, 5.27) 
1.29 
(0.27, 6.12) 
0.45 
(0.09, 2.37) 
0.52 
(0.10, 2.65) 
0.57 
(0.16, 2.08) 
0.65 
(0.18, 2.43) 
0.36 
(0.06, 2.26) 
0.74 
(0.19, 2.86) 
 
IMI 
-0.02 
(-0.81, 0.76) 
-0.01 
(-0.72, 0.70) 
0.03 
(-0.81, 0.87) 
0.03 
(-0.64, 0.70) 
0.06 
(-0.69, 0.81) 
0.14 
(-0.66, 0.94) 
0.25 
(-0.50, 0.99) 
0.37 
(-0.67, 1.41) 
0.27 
(-0.39, 0.92) 
0.33 
(-0.39, 1.04) 
0.40 
(-0.38, 1.18) 
0.59 
(-0.28, 1.47) 
_ 
11.75 
(2.15, 64.07) 
1.83 
(0.28, 11.98) 
3.70 
(1.09, 12.57) 
1.30 
(0.34, 4.98) 
1.50 
(0.41, 5.55) 
1.63 
(0.68, 3.89) 
1.88 
(0.77, 4.58) 
1.04 
(0.22, 4.92) 
2.12 
(0.81, 5.50) 
2.87 
(0.62, 13.22) 
 
TPM 
0.02 
(-0.49, 0.52) 
0.05 
(-0.62, 0.73) 
0.05 
(-0.39, 0.50) 
0.08 
(-0.47, 0.64) 
0.17 
(-0.46, 0.79) 
0.27 
(-0.28, 0.82) 
0.39 
(-0.52, 1.31) 
0.29 
(-0.14, 0.71) 
0.35 
(-0.15, 0.85) 
0.42 
(-0.17, 1.02) 
0.62 
(-0.09, 1.33) 
_ 
12.81 
(2.32, 70.73) 
1.99 
(0.30, 13.21) 
4.04 
(0.30, 13.94) 
1.42 
(0.37, 5.52) 
1.64 
(0.44, 6.15) 
1.78 
(0.73, 4.35) 
2.05 
(0.82, 5.11) 
1.13 
(0.24, 5.44) 
2.31 
(0.87, 6.13) 
3.13 
(0.67, 14.61) 
1.09 
(0.33, 3.63) 
 
RIS 
0.04 
(-0.54, 0.62) 
0.04 
(-0.26, 0.34) 
0.07 
(-0.37, 0.51) 
0.15 
(-0.37, 0.67) 
0.25 
(-0.18, 0.69) 
0.38 
(-0.47, 1.23) 
0.27 
(0.01, 0.54) 
0.33 
(-0.04, 0.71) 
0.41 
(-0.09, 0.90) 
0.60 
(-0.02, 1.23) 
_ 
10.45 
(1.48, 73.64) 
1.63 
(0.20, 13.47) 
3.29 
(0.69, 15.65) 
1.16 
(0.22, 6.06) 
1.33 
(0.26, 6.79) 
1.45 
(0.40, 5.33) 
1.67 
(0.45, 6.23) 
0.92 
(0.15, 5.77) 
1.88 
(0.48, 7.33) 
2.55 
(0.42, 15.56) 
0.89 
(0.19, 4.10) 
0.82 
(0.17, 3.81) 
 
NEF 
0.00 
(-0.52, 0.52) 
0.03 
(-0.60, 0.66) 
0.11 
(-0.58, 0.80) 
0.21 
(-0.41, 0.84) 
0.34 
(-0.63, 1.30) 
0.23 
(-0.29, 0.76) 
0.29 
(-0.29, 0.88) 
0.37 
(-0.30, 1.04) 
0.56 
(-0.20, 1.33) 
_ 
8.32 
(1.87, 37.08) 
1.29 
(0.24, 7.09) 
2.62 
(1.05, 6.59) 
0.92 
(0.32, 2.70) 
1.06 
(0.38, 2.99) 
1.16 
(0.83, 1.61) 
1.33 
(0.95, 1.87) 
0.74 
(0.19, 2.79) 
1.50 
(0.90, 2.51) 
2.03 
(0.56, 7.45) 
0.71           
(0.30, 1.69) 
0.65 
(0.27, 1.59) 
0.80 
(0.22, 2.93) 
 
SER 
0.03 
(-0.35, 0.41) 
0.11 
(-0.36, 0.58) 
0.21 
(-0.16, 0.59) 
0.34 
(-0.48, 1.16) 
0.23 
(0.09, 0.38) 
0.29 
(-0.01, 0.59) 
0.37 
(-0.07, 0.81) 
0.56 
(0.00, 1.13) 
_ 
9.04 
(1.78, 45.88) 
1.41 
(0.23, 8.64) 
2.85 
(0.93, 8.74) 
1.00 
(0.29, 3.50) 
1.15 
(0.34, 3.89) 
1.26 
(0.61, 2.58) 
1.45 
(0.69, 3.05) 
0.80 
(0.18, 3.50) 
1.63 
(0.72, 3.70) 
2.21 
(0.52, 9.39) 
0.77 
(0.26, 2.26) 
0.71 
(0.24, 2.12) 
0.86 
(0.20, 3.68) 
1.09 
(0.53, 2.23) 
 
NK1R 
0.08 
(-0.49, 0.66) 
0.19 
(-0.31, 0.68) 
0.31 
(-0.58, 1.19) 
0.20 
(-0.15, 0.56) 
0.26 
(-0.18, 0.71) 
0.34 
(-0.21, 0.89) 
0.54 
(-0.14, 1.21) 
_ 
12.91 
(2.10, 79.49) 
2.01 
(0.27, 14.70) 
4.07 
(1.02, 16.27) 
1.43 
(0.32, 6.37) 
1.65 
(0.38, 7.12) 
1.79 
(0.61, 5.32) 
2.07 
(0.69, 6.23) 
1.14 
(0.21, 6.17) 
2.33 
(0.73, 7.39) 
3.16 
(0.60, 16.60) 
1.10 
(0.28, 4.25) 
1.01 
(0.26, 3.96) 
1.24 
(0.23, 6.52) 
1.55 
(0.52, 4.60) 
1.43 
(0.41, 5.04) 
 
GUA 
0.10 
(-0.47, 0.68) 
0.23 
(-0.70, 1.16) 
0.12 
(-0.33, 0.58) 
0.18 
(-0.34, 0.71) 
0.26 
(-0.36, 0.87) 
0.45 
(-0.27, 1.18) 
_ 
4.68 
(0.97, 22.43) 
0.73 
(0.12, 4.25) 
1.47 
(0.52, 4.16) 
0.52 
(0.16, 1.68) 
0.60 
(0.19, 1.86) 
0.65 
(0.36, 1.16) 
0.75 
(0.41, 1.38) 
0.41 
(0.10, 1.70) 
0.84 
(0.42, 1.70) 
1.14 
(0.29, 4.56) 
0.40 
(0.15, 1.07) 
0.37 
(0.13, 1.00) 
0.45 
(0.11, 1.79) 
0.56 
(0.31, 1.00) 
0.52 
(0.22, 1.23) 
0.36 
(0.11, 1.19) 
 
TGB 
0.12 
(-0.76, 1.00) 
0.02 
(-0.33, 0.37) 
0.08 
(-0.51, 0.36) 
0.15 
(-0.39, 0.70) 
0.35 
(-0.32, 1.02) 
_ 
10.00 
(0.94,106.64) 
1.56 
(0.13, 18.99) 
3.15 
(0.40, 24.58) 
1.11 
(0.13, 9.31) 
1.28 
(0.16, 10.50) 
1.39 
(0.22, 8.97) 
1.60 
(0.25, 10.44) 
0.89 
(0.09, 8.55) 
1.80 
(0.27, 12.13) 
2.44 
(0.26, 23.15) 
0.85 
(0.11, 6.49) 
0.78 
(0.10, 6.01) 
0.96 
(0.10, 9.08) 
1.20 
(0.19, 7.76) 
1.11 
(0.15, 7.95) 
0.77 
(0.09, 6.54) 
2.14 
(0.31, 14.67) 
 
BUP 
-0.10 
(-0.91, 0.71) 
0.05 
(-0.81, 0.90) 
0.03 
(-0.88, 0.94) 
0.23 
(-0.76, 1.22) 
_ 
7.50 
(1.72,32.80) 
1.17 
(0.22, 6.28) 
2.36 
(0.97, 5.76) 
0.83 
(0.29, 2.37) 
0.96 
(0.35, 2.62) 
1.04 
(0.82, 1.32) 
1.20 
(0.89, 1.63) 
0.66 
(0.18, 2.46) 
1.35 
(0.85, 2.14) 
1.83 
(0.51, 6.57) 
0.64 
(0.28, 1.48) 
0.59 
(0.25, 1.39) 
0.72 
(0.20, 2.58) 
0.90 
(0.71, 1.14) 
0.83 
(0.42, 1.64) 
0.58 
(0.20, 1.68) 
1.60 
(0.94, 2.73) 
0.75 
(0.12, 4.77) 
 
PLB 
0.06 
(-0.20, 0.32) 
0.13 
(-0.28, 0.55) 
0.33 
(-0.24, 0.90) 
_ 
7.87 
(1.66, 37.31) 
1.22 
(0.21, 7.08) 
2.48 
(0.89, 6.87) 
0.87 
(0.27, 2.78) 
1.01 
(0.33, 3.08) 
1.09 
(0.63, 1.89) 
1.26 
(0.70, 2.25) 
0.70 
(0.17, 2.83) 
1.42 
(0.72, 2.79) 
1.92 
(0.49, 7.56) 
0.67 
(0.25, 1.77) 
0.61 
(0.23, 1.66) 
0.75 
(0.19, 2.97) 
0.94 
(0.55, 1.64) 
0.87 
(0.37, 2.02) 
0.61 
(0.19, 1.97) 
1.68 
(0.81, 3.48) 
0.79 
(0.12, 5.34) 
1.05 
(0.64, 1.72) 
PRZ 0.07 
(-0.41, 0.57) 
0.27 
(-0.36, 0.90) 
 
8.21 
(1.48, 45.51) 
1.28 
(0.19, 8.50) 
2.59 
(0.75, 8.98) 
0.91 
(0.23, 3.56) 
1.05 
(0.28, 3.96) 
1.14 
(0.46, 2.81) 
1.31 
(0.52, 3.30) 
0.73 
(0.15, 3.50) 
1.48 
(0.55, 3.95) 
2.01 
(0.43, 9.40) 
0.70 
(0.21, 2.34) 
0.64 
(0.19, 2.18) 
0.79 
(0.17, 3.69) 
0.99 
(0.40, 2.43) 
0.91 
(0.30, 2.74) 
0.64 
(0.16, 2.51) 
1.76 
(0.63, 4.86) 
0.82 
(0.11, 6.35) 
1.10 
(0.46, 2.61) 
1.04 
(0.38, 2.84) 
 
DVP 
0.20 
(-0.51, 0.90) 
_ 
5.58 
(0.81,38.61) 
0.87 
(0.11, 7.07) 
1.76 
(0.38, 8.17) 
0.62 
(0.12, 3.17) 
0.71 
(0.14, 3.55) 
0.77 
(0.22, 2.77) 
0.89 
(0.25, 3.21) 
0.49 
(0.08, 3.02) 
1.00 
(0.26, 3.81) 
1.36 
(0.23, 8.15) 
0.47 
(0.11, 2.14) 
0.44 
(0.10, 1.99) 
0.53 
(0.09, 3.20) 
0.67 
(0.19, 2.32) 
0.62 
(0.15, 2.57) 
0.43 
(0.08, 2.23) 
1.19 
(0.31, 4.65) 
0.56 
(0.06, 5.21) 
0.74 
(0.21, 2.60) 
0.71 
(0.18, 2.73) 
0.68 
(0.15, 3.12) 
 
CIT 
_ 
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0.94 
(0.05, 19.02) 
0.15 
(0.01, 3.29) 
0.30 
(0.02, 4.72) 
0.10 
(0.01, 1.75) 
0.12 
(0.01, 1.99) 
0.13 
(0.01, 1.81) 
0.15 
(0.01, 2.10) 
 
0.08 
(0.00, 1.56) 
0.17 
(0.01, 2.42) 
0.23 
(0.01, 4.24) 
0.08 
(0.01, 1.25) 
0.07 
(0.00, 1.16) 
0.09 
(0.00, 1.66) 
0.11 
(0.01, 1.57) 
0.10 
(0.01, 1.56) 
0.07 
(0.00, 1.23) 
0.20 
(0.01, 2.92) 
0.09 
(0.00, 
2.32) 
0.12 
(0.01, 1.72) 
0.12 
(0.01, 1.72) 
0.11 
(0.01, 1.81) 
0.17 
(0.01, 3.08) 
 
LAM 
 
 
Table 1. NMA results for the two primary outcomes. Legend: Mean change in symptoms severity (green) and all-cause dropout rate (blue). For efficacy 
(green), standardized mean difference values greater than 0 indicated that the treatment specified in the row is more efficacious. For acceptability, odds 
ratios greater than 1 indicated that the treatment specified in the column is better (fewer dropouts). Bold underlined results indicate statistical significance. 
The overall heterogeneity (𝜏) is equal to 0.1 for efficacy and equal to 0 for acceptability. For efficacy, I2 was 22.4% for heterogeneity and 22.5% for 
inconsistency; for acceptability, I2 was 0% for heterogeneity and 8% for inconsistency.  AMI: amitriptyline; BRO: bromipramine; BUP: bupropion; CIT: 
citalopram; DES: desipramine; DVP: divalproex; FLX: fluoxetine; GUA: guanfacine; IMI: imipramine; LAM: lamotrigine; MIR: mirtazapine; NEF: nefazodone; 
NK1R: NK1 receptor antagonist; OLA: olanzapine; PAR: paroxetine; PHE: phenelzine; PLB: placebo; PRZ: prazosin; RIS: risperidone; SER: sertraline; TGB: 
tiagabine; TPM: topiramate; VEN: venlafaxine. 
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